AI assistant
Altimmune, Inc. — Director's Dealing 2020
May 18, 2020
33207_dirs_2020-05-18_ef4b0679-a243-4196-af0c-1aa342fd0fcd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2020-05-14
Reporting Person: VELOCITY PHARMACEUTICAL HOLDINGS LLC (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-05-14 | Common Stock | S | 169378 | $4.81 | Disposed | 1717872 | Direct |
| 2020-05-15 | Common Stock | S | 30622 | $4.65 | Disposed | 1687250 | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.65 to $5.02. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.
F2: The shares are directly held by Velocity Pharmaceutical Holdings LLC ("VPH"). Velocity Pharma Management, LLC ("VPM") is the manager of VPH. David J. Collier and James F. Watson are the managing members of VPM, and as such may be deemed to hold shared voting and dispositive power over the shares held by VPH. Mr. Collier and Mr. Watson disclaim beneficial ownership of the shares held by VPH except to the extent of their pecuniary interest therein.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.40 to $4.70. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.